Cargando…

Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer

Preventing breast cancer is an effective strategy for reducing breast cancer deaths. The purpose of chemoprevention (also termed preventive therapy) is to reduce cancer incidence by use of natural, synthetic, or biological agents. The efficacy of tamoxifen, raloxifene, and exemestane as preventive t...

Descripción completa

Detalles Bibliográficos
Autores principales: Litzenburger, Beate C., Brown, Powel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015058/
https://www.ncbi.nlm.nih.gov/pubmed/24829621
http://dx.doi.org/10.1007/s12609-014-0144-1
_version_ 1782315281467572224
author Litzenburger, Beate C.
Brown, Powel H.
author_facet Litzenburger, Beate C.
Brown, Powel H.
author_sort Litzenburger, Beate C.
collection PubMed
description Preventing breast cancer is an effective strategy for reducing breast cancer deaths. The purpose of chemoprevention (also termed preventive therapy) is to reduce cancer incidence by use of natural, synthetic, or biological agents. The efficacy of tamoxifen, raloxifene, and exemestane as preventive therapy against estrogen-receptor (ER)-positive breast cancer is well established for women at increased risk for breast cancer. However, because breast cancer is a heterogeneous disease, distinct preventive approaches may be required for effective prevention of each subtype. Current research is, therefore, focused on identifying alternative mechanisms by which biologically active compounds can reduce the risk of all breast cancer subtypes including ER-negative breast cancer. Promising agents are currently being developed for prevention of HER2-positive and triple-negative breast cancer (TNBC) and include inhibitors of the ErbB family receptors, COX-2 inhibitors, metformin, retinoids, statins, poly(ADP-ribose) polymerase inhibitors, and natural compounds. This review focuses on recent progress in research to develop more effective preventive agents, in particular for prevention of ER-negative breast cancer.
format Online
Article
Text
id pubmed-4015058
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-40150582014-05-12 Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer Litzenburger, Beate C. Brown, Powel H. Curr Breast Cancer Rep Risk, Prevention, and Screening (TA Patel, Section Editor) Preventing breast cancer is an effective strategy for reducing breast cancer deaths. The purpose of chemoprevention (also termed preventive therapy) is to reduce cancer incidence by use of natural, synthetic, or biological agents. The efficacy of tamoxifen, raloxifene, and exemestane as preventive therapy against estrogen-receptor (ER)-positive breast cancer is well established for women at increased risk for breast cancer. However, because breast cancer is a heterogeneous disease, distinct preventive approaches may be required for effective prevention of each subtype. Current research is, therefore, focused on identifying alternative mechanisms by which biologically active compounds can reduce the risk of all breast cancer subtypes including ER-negative breast cancer. Promising agents are currently being developed for prevention of HER2-positive and triple-negative breast cancer (TNBC) and include inhibitors of the ErbB family receptors, COX-2 inhibitors, metformin, retinoids, statins, poly(ADP-ribose) polymerase inhibitors, and natural compounds. This review focuses on recent progress in research to develop more effective preventive agents, in particular for prevention of ER-negative breast cancer. Springer US 2014-03-25 2014 /pmc/articles/PMC4015058/ /pubmed/24829621 http://dx.doi.org/10.1007/s12609-014-0144-1 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Risk, Prevention, and Screening (TA Patel, Section Editor)
Litzenburger, Beate C.
Brown, Powel H.
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer
title Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer
title_full Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer
title_fullStr Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer
title_full_unstemmed Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer
title_short Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer
title_sort advances in preventive therapy for estrogen-receptor-negative breast cancer
topic Risk, Prevention, and Screening (TA Patel, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015058/
https://www.ncbi.nlm.nih.gov/pubmed/24829621
http://dx.doi.org/10.1007/s12609-014-0144-1
work_keys_str_mv AT litzenburgerbeatec advancesinpreventivetherapyforestrogenreceptornegativebreastcancer
AT brownpowelh advancesinpreventivetherapyforestrogenreceptornegativebreastcancer